EXACT Sciences Corporation (EXAS) Shares are Up 3.03%

EXACT Sciences Corporation (EXAS) has been under a strong bear grip, hence the stock is down -4.16% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.48% in the past 1 week. The stock has risen by 3.03% in the past week indicating that the buyers are active at lower levels, but the stock is down -6.1% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 0.36% and the 50-Day Moving Average is 11.03%.The 200 Day SMA reached 96.22% Exact Sciences Corporation is up 76.85% in the last 3-month period. Year-to-Date the stock performance stands at 110.18%.


EXACT Sciences Corporation (EXAS) : The highest short term price target forecast on EXACT Sciences Corporation (EXAS) is $26 and the lowest target price is $8. A total of 9 equity analysts are currently covering the company. The average price of all the analysts is $15.78 with a standard deviation of $5.91.

For the current week, the company shares have a recommendation consensus of Buy. EXACT Sciences Corporation (NASDAQ:EXAS): The stock opened at $19 and touched an intraday high of $19.77 on Friday. During the day, the stock corrected to an intraday low of $18.99, however, the bulls stepped in and pushed the price higher to close in the green at $19.4 with a gain of 0.73% for the day. The total traded volume for the day was 3,903,507. The stock had closed at $19.4 in the previous trading session.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.